Teva To Pay $270M In Propofol Hepatitis Suits

Law360, New York (February 21, 2012, 4:07 PM EST) -- Teva Pharmaceuticals Industries Ltd. will spend roughly $270 million on suits claiming the way it packaged its anesthetic Propofol caused a hepatitis C outbreak, Teva told securities regulators Friday, revealing it had settled most of the cases in the Nevada-based litigation.

Teva is still a defendant in 50 Nevada-based state court suits, the drugmaker said in its U.S. Securities and Exchange Commission filing, which revealed that it had spent or set aside to date $270 million for the suits, 120 of which have been settled. Teva...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.